Covaxin, being developed in collaboration with the Indian Council of Medical Research and the National Institute of Virology, is now undergoing phase-3 trials

DCGI gives a green signal to SII, India will be the first nation to approve the Oxford vaccine under emergency use authorisation; British health regulator is still evaluating Oxford-AstraZeneca data

The Phase 3 clinical trials of Covaxin began in mid-November with a target of 26,000 volunteers. Bharat Biotech's is the first and only Phase 3 efficacy study for a vaccine developed in the country

SII had earlier said its vaccine candidate showed 90 per cent efficacy rate at a full dose plus a half dose regimen, while a 62 per cent efficacy rate at full two-dose regimen

The All India Institute of Medical Sciences (AIIMS) in the national capital is one of the sites conducting the final phase of the trial of the vaccine, \"Covaxin\", and it needs around 1,500 volunteers for the purpose

Last month, 67-year-old Anil Vij volunteered himself for Bharat Biotech's coronavirus vaccine trial. The firebrand BJP leader had offered to be the first volunteer in the phase three trials for Covaxin

Foreign banks, capital from abroad can remedy India's bad debt: Abhijit Banerjee As discussion continues whether private players should be allowed in the Indian banking space, Nobel laureate Abhijit Banerjee pointed out how foreign participation can save the bleeding sector. Banerjee said that Indian banks need a huge capital infusion to stay viable that can come easily from foreign sources. Banerjee noted that once we take on the view that the banking sector needs more private ownership, r...

The humongous amounts of data that will be generated during the global vaccination process needs to be analysed almost real-time. That's where an integrated SCM suite embedded with emerging technology comes in

An expert committee of the Central Drugs Standard Control Organisation (CDSCO) sought additional safety and efficacy data for COVID-19 vaccine candidates of Bharat Biotech after deliberating upon its applications seeking emergency use authorisation for the shots

Out of 22,000 volunteers, the company has already recruited around 8,000 volunteers, says Krishna Ella, Chairman and Managing Director of Bharat Biotech

As the country plans to vaccinate 30 crore people by July in the first phase, it may be difficult to bank alone on the Indian vaccines, especially Serum Institute's (SII) Covishield

Both Pfizer and Moderna have admitted that taking their vaccines could result in side-effects similar to mild Covid symptoms such as muscle pain, chills and a headache

The Subject Expert Committee (SEC), a government panel tasked with vetting coronavirus vaccines, has asked Bharat Biotech and Serum Institute of India (SII) to submit updated country-specific trial data of their vaccine candidates Covaxin and Covishield

Several experts have raised questions about Bharat Biotech applying for emergency usage as Covaxin is still going through an efficacy trial. However, the ICMR has backed Bharat Biotech's move

Over the last four days, the Indian arm of US pharmaceutical giant Pfizer, Pune-based Serum Institute of India and Hyderabad-based pharmaceutical firm Bharat Biotech have applied to the Drugs Controller General of India (DCGI) seeking emergency use authorisation

 Bharat Biotech said its vaccine is safe and efficacious  after Haryana Home Minister Anil Vij tested positive for the viral disease despite taking the first shot of the medication

The vaccine developer said on Saturday that the Covaxin clinical trials are based on a 2-dose routine, the two doses are administered 28 days apart and vaccine efficacy will be determined 14 days post the second dose

The 67-year-old BJP leader, who's also the home minister in the Khattar Cabinet, has requested everyone who might have come in his contact to get tested. He was the first volunteer in the phase three trials for Covaxin to get the vaccine shot

DCGI VG Somani has said the CDSCO will facilitate analysis of interim clinical trial data at pre-defined stages. PM Modi says nearly eight vaccine candidates, out of which three are indigenously developed, are undergoing trials in India

COVID-19 vaccine trial updates: AIIMS director Dr Randeep Guleria has pinned his hopes on the five coronavirus vaccine candidates which are in varying stages of trials across India